Version 1
: Received: 26 October 2023 / Approved: 27 October 2023 / Online: 27 October 2023 (08:17:30 CEST)
How to cite:
Cho, H.; Han, K.-H.; Chung, J.-S.; Byun, S.-S.; Chung, J. I.; Seo, W. I.; Lee, C. H. Precise Detection and Transcriptomic Concordant Analysis of Circulating Tumor Cells from Prostate Cancer. Preprints2023, 2023101760. https://doi.org/10.20944/preprints202310.1760.v1
Cho, H.; Han, K.-H.; Chung, J.-S.; Byun, S.-S.; Chung, J. I.; Seo, W. I.; Lee, C. H. Precise Detection and Transcriptomic Concordant Analysis of Circulating Tumor Cells from Prostate Cancer. Preprints 2023, 2023101760. https://doi.org/10.20944/preprints202310.1760.v1
Cho, H.; Han, K.-H.; Chung, J.-S.; Byun, S.-S.; Chung, J. I.; Seo, W. I.; Lee, C. H. Precise Detection and Transcriptomic Concordant Analysis of Circulating Tumor Cells from Prostate Cancer. Preprints2023, 2023101760. https://doi.org/10.20944/preprints202310.1760.v1
APA Style
Cho, H., Han, K. H., Chung, J. S., Byun, S. S., Chung, J. I., Seo, W. I., & Lee, C. H. (2023). Precise Detection and Transcriptomic Concordant Analysis of Circulating Tumor Cells from Prostate Cancer. Preprints. https://doi.org/10.20944/preprints202310.1760.v1
Chicago/Turabian Style
Cho, H., Won Ik Seo and Chan Ho Lee. 2023 "Precise Detection and Transcriptomic Concordant Analysis of Circulating Tumor Cells from Prostate Cancer" Preprints. https://doi.org/10.20944/preprints202310.1760.v1
Abstract
This study focused on the precise detection and concordant analysis of circulating tumor cells (CTCs) to verify the usefulness of CTCs as promising clinical markers. CTCs are traditionally achieved using immune-fluorescence and morphological techniques. By combining two prostate cancer-specific genes (PSA and PSMA) and two epithelial-specific genes (EpCAM and KRT19), the CTC detection efficiency can be enhanced. The detection rates of localized prostate cancer (LPC), locally advanced prostate cancer (LAPC), metastatic hormone-sensitive prostate cancer (mHSPC), and metastatic castration-resistive prostate cancer (mCRPC) were 63.04 % (29/46), 70.59% (34/51), 94.34% (50/53), and 90% (126/140), respectively. Subsequent correlation analysis between the four genes, baseline PSA, and CTC count revealed that only the CTC count correlated with baseline PSA in the localized stages of prostate cancer, whereas all four genes were correlated with baseline PSA and CTC count in the metastatic stages of prostate cancer. The precise detection of CTCs using both numerical and transcriptomic analyses can improve the accuracy of biomarker investigations. This study provides valuable insights into the limitations of serum PSA testing and offers a promising alternative to diagnose and manage prostate cancer via the CTC number and specific genes for prostate cancer.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.